RXRX (Recursion) סך נכסי החברה

Recursion Pharmaceuticals (RXRX) is transforming drug discovery by leveraging neural networks to rapidly identify biological targets. Total assets on this chart confirm a growing base, where the 1257.59 metric serves as the target level. AI automation in genetics and oncology minimizes pipeline risks, while the alliance with NVIDIA and powerful supercomputers provide the company with a significant technological moat.

For Recursion Pharmaceuticals (RXRX), which integrates robotic laboratories and AI, total assets represent the aggregate resource base necessary to scale breakthrough biomedical research. The current calculation of total assets at 1257.59 was derived reverse-engineered via ROA, allowing investors to assess the actual volume of assets and liabilities to determine the financial stability of this innovative development model.